Could new breakthrough in Parkinson’s treatment stop the disease?

New breakthrough in Parkinson’s treatment ‘could one day stop the disease’. The study in Finland builds on work of the GDNF drug, which has shown promise in restoring damaged cells in Parkinson’s patients but is difficult to administer.

Could bt13 be a new breakthrough in Parkinson’s disease treatment?

Why scientists believe they’ve made new breakthrough in Parkinson’s disease treatment by building on GDNF research The Finnish researchers are now working to improve the properties of BT13 to make it more effective as a potential treatment that could benefit many people living with the disease.

Could a new family of compounds slow the progression of Parkinson’s disease?

CHICAGO — In an early-stage breakthrough, a team of Northwestern University scientists has developed a new family of compounds that could slow the progression of Parkinson’s disease. Parkinson’s, the second most common neurodegenerative disease, is caused by the death of dopamine neurons, resulting in tremors, rigidity and difficulty moving.

What is Parkinson’s disease?

Parkinson’s, the second most common neurodegenerative disease, is caused by the death of dopamine neurons, resulting in tremors, rigidity and difficulty moving. Current treatments target the symptoms but do not slow the progression of the disease.

Parkinson’s is a long-term degenerative disorder of the central nervous system that includes symptoms such as tremors, slowness of movement and rigidity (Credit: Facebook/Parkinson’s UK) Scientists have discovered a molecule that could provide a breakthrough in providing new treatments to slow down or even stop Parkinson’s disease.

Could a ‘genetic signature’ open the door to New Parkinson’s treatments?

Scientists at La Jolla Institute for Immunology (LJI) have found that people with Parkinson’s disease have a clear “genetic signature” of the disease in their memory T cells. The scientists hope that targeting these genes may open the door to new Parkinson’s treatments and diagnostics.